Analytical Data
-
Gene name
S100A7
- Application
-
Alternative Names
S100-A7; PSOR1; S100A7c; Psoriasin 1
-
Species
Bovine
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q28050
-
Expression Region
Met1~Gln101
-
Molecular Weight
38kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
S100A7, also known as psoriasin, is a member of the S100 family of calcium-binding proteins, which are involved in various cellular processes, including cell proliferation, differentiation, and inflammation. Initially discovered in the context of psoriasis, S100A7 is highly expressed in the epidermis and has been implicated in the pathogenesis of several inflammatory skin disorders. Its overexpression is associated with abnormal keratinocyte function and contributes to the inflammatory response in these conditions. Beyond dermatological implications, recent studies have suggested that S100A7 may play a role in cancer progression and metastasis, particularly in breast cancer, where it is linked to poor prognosis. The production of recombinant S100A7 protein has been pursued to facilitate research into its biological functions, interactions with other proteins, and potential therapeutic applications. By using recombinant technology, researchers aim to elucidate the structure-function relationships of S100A7, explore its signaling pathways, and assess its role in modulating immune responses. Understanding the mechanistic role of S100A7 in both inflammation and cancer may provide valuable insights for the development of novel therapeutic strategies targeting its pathways, ultimately leading to improved treatment options for patients suffering from related diseases.
